Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer

Akitaka Makiyama, Kohei Arimizu, Gen Hirano, Chinatsu Makiyama, Yuzo Matsushita, Tsuyoshi Shirakawa, Hirofumi Ohmura, Masato Komoda, Keita Uchino, Kyoko Inadomi, Shuji Arita, hiroshi ariyama, Hitoshi Kusaba, Yudai Shinohara, Miyuki Kuwayama, Tatsuhiro Kajitani, Hisanobu Oda, Taito Esaki, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Background: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. Methods: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. Results: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75.3% had prior platinum therapy. The median age was 66 (range 27–81) years, and 102 males (69.9%) were included. Performance status (PS) was 0/1/2/3 in 53/70/19/4 patients. Eighty-nine patients (61.0%) had two or more metastatic sites. Irinotecan monotherapy as 3rd-/4th-line therapy was performed in 135/11 (92.5%/7.5%). The median number of administrations was 4 (range 1–62). Forty-six patients (31.5%) required initial dose reduction at the physician’s discretion. The overall response rate was 6.8%, and the disease control rate was 43.1%. The median PFS was 3.19 months [95% confidence interval (CI) 2.30–4.08 months], and the median OS was 6.61 months (95% CI 5.94–7.28 months). Grade 3/4 adverse events were hematological toxicity (46 patients, 31.5%) and non-hematological toxicity (50 patients, 34.2%). Hospitalization due to adverse events was required in 31 patients (21.2%). Patients with relative dose intensity (RDI) less than 80% showed similar survival to those with RDI 80% or higher. Conclusions: Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.

元の言語英語
ページ(範囲)464-472
ページ数9
ジャーナルGastric Cancer
21
発行部数3
DOI
出版物ステータス出版済み - 5 1 2018

Fingerprint

irinotecan
Stomach Neoplasms
Salvage Therapy
Therapeutics
Survival
Confidence Intervals

All Science Journal Classification (ASJC) codes

  • Oncology
  • Gastroenterology
  • Cancer Research

これを引用

Makiyama, A., Arimizu, K., Hirano, G., Makiyama, C., Matsushita, Y., Shirakawa, T., ... Baba, E. (2018). Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric Cancer, 21(3), 464-472. https://doi.org/10.1007/s10120-017-0759-9

Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. / Makiyama, Akitaka; Arimizu, Kohei; Hirano, Gen; Makiyama, Chinatsu; Matsushita, Yuzo; Shirakawa, Tsuyoshi; Ohmura, Hirofumi; Komoda, Masato; Uchino, Keita; Inadomi, Kyoko; Arita, Shuji; ariyama, hiroshi; Kusaba, Hitoshi; Shinohara, Yudai; Kuwayama, Miyuki; Kajitani, Tatsuhiro; Oda, Hisanobu; Esaki, Taito; Akashi, Koichi; Baba, Eishi.

:: Gastric Cancer, 巻 21, 番号 3, 01.05.2018, p. 464-472.

研究成果: ジャーナルへの寄稿記事

Makiyama, A, Arimizu, K, Hirano, G, Makiyama, C, Matsushita, Y, Shirakawa, T, Ohmura, H, Komoda, M, Uchino, K, Inadomi, K, Arita, S, ariyama, H, Kusaba, H, Shinohara, Y, Kuwayama, M, Kajitani, T, Oda, H, Esaki, T, Akashi, K & Baba, E 2018, 'Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer', Gastric Cancer, 巻. 21, 番号 3, pp. 464-472. https://doi.org/10.1007/s10120-017-0759-9
Makiyama A, Arimizu K, Hirano G, Makiyama C, Matsushita Y, Shirakawa T その他. Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. Gastric Cancer. 2018 5 1;21(3):464-472. https://doi.org/10.1007/s10120-017-0759-9
Makiyama, Akitaka ; Arimizu, Kohei ; Hirano, Gen ; Makiyama, Chinatsu ; Matsushita, Yuzo ; Shirakawa, Tsuyoshi ; Ohmura, Hirofumi ; Komoda, Masato ; Uchino, Keita ; Inadomi, Kyoko ; Arita, Shuji ; ariyama, hiroshi ; Kusaba, Hitoshi ; Shinohara, Yudai ; Kuwayama, Miyuki ; Kajitani, Tatsuhiro ; Oda, Hisanobu ; Esaki, Taito ; Akashi, Koichi ; Baba, Eishi. / Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer. :: Gastric Cancer. 2018 ; 巻 21, 番号 3. pp. 464-472.
@article{c72675775e2c4d3e8fcaf5ab17b4dae8,
title = "Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer",
abstract = "Background: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. Methods: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. Results: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75.3{\%} had prior platinum therapy. The median age was 66 (range 27–81) years, and 102 males (69.9{\%}) were included. Performance status (PS) was 0/1/2/3 in 53/70/19/4 patients. Eighty-nine patients (61.0{\%}) had two or more metastatic sites. Irinotecan monotherapy as 3rd-/4th-line therapy was performed in 135/11 (92.5{\%}/7.5{\%}). The median number of administrations was 4 (range 1–62). Forty-six patients (31.5{\%}) required initial dose reduction at the physician’s discretion. The overall response rate was 6.8{\%}, and the disease control rate was 43.1{\%}. The median PFS was 3.19 months [95{\%} confidence interval (CI) 2.30–4.08 months], and the median OS was 6.61 months (95{\%} CI 5.94–7.28 months). Grade 3/4 adverse events were hematological toxicity (46 patients, 31.5{\%}) and non-hematological toxicity (50 patients, 34.2{\%}). Hospitalization due to adverse events was required in 31 patients (21.2{\%}). Patients with relative dose intensity (RDI) less than 80{\%} showed similar survival to those with RDI 80{\%} or higher. Conclusions: Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.",
author = "Akitaka Makiyama and Kohei Arimizu and Gen Hirano and Chinatsu Makiyama and Yuzo Matsushita and Tsuyoshi Shirakawa and Hirofumi Ohmura and Masato Komoda and Keita Uchino and Kyoko Inadomi and Shuji Arita and hiroshi ariyama and Hitoshi Kusaba and Yudai Shinohara and Miyuki Kuwayama and Tatsuhiro Kajitani and Hisanobu Oda and Taito Esaki and Koichi Akashi and Eishi Baba",
year = "2018",
month = "5",
day = "1",
doi = "10.1007/s10120-017-0759-9",
language = "English",
volume = "21",
pages = "464--472",
journal = "Gastric Cancer",
issn = "1436-3291",
publisher = "Springer Japan",
number = "3",

}

TY - JOUR

T1 - Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer

AU - Makiyama, Akitaka

AU - Arimizu, Kohei

AU - Hirano, Gen

AU - Makiyama, Chinatsu

AU - Matsushita, Yuzo

AU - Shirakawa, Tsuyoshi

AU - Ohmura, Hirofumi

AU - Komoda, Masato

AU - Uchino, Keita

AU - Inadomi, Kyoko

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Kusaba, Hitoshi

AU - Shinohara, Yudai

AU - Kuwayama, Miyuki

AU - Kajitani, Tatsuhiro

AU - Oda, Hisanobu

AU - Esaki, Taito

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. Methods: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. Results: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75.3% had prior platinum therapy. The median age was 66 (range 27–81) years, and 102 males (69.9%) were included. Performance status (PS) was 0/1/2/3 in 53/70/19/4 patients. Eighty-nine patients (61.0%) had two or more metastatic sites. Irinotecan monotherapy as 3rd-/4th-line therapy was performed in 135/11 (92.5%/7.5%). The median number of administrations was 4 (range 1–62). Forty-six patients (31.5%) required initial dose reduction at the physician’s discretion. The overall response rate was 6.8%, and the disease control rate was 43.1%. The median PFS was 3.19 months [95% confidence interval (CI) 2.30–4.08 months], and the median OS was 6.61 months (95% CI 5.94–7.28 months). Grade 3/4 adverse events were hematological toxicity (46 patients, 31.5%) and non-hematological toxicity (50 patients, 34.2%). Hospitalization due to adverse events was required in 31 patients (21.2%). Patients with relative dose intensity (RDI) less than 80% showed similar survival to those with RDI 80% or higher. Conclusions: Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.

AB - Background: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. Methods: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. Results: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75.3% had prior platinum therapy. The median age was 66 (range 27–81) years, and 102 males (69.9%) were included. Performance status (PS) was 0/1/2/3 in 53/70/19/4 patients. Eighty-nine patients (61.0%) had two or more metastatic sites. Irinotecan monotherapy as 3rd-/4th-line therapy was performed in 135/11 (92.5%/7.5%). The median number of administrations was 4 (range 1–62). Forty-six patients (31.5%) required initial dose reduction at the physician’s discretion. The overall response rate was 6.8%, and the disease control rate was 43.1%. The median PFS was 3.19 months [95% confidence interval (CI) 2.30–4.08 months], and the median OS was 6.61 months (95% CI 5.94–7.28 months). Grade 3/4 adverse events were hematological toxicity (46 patients, 31.5%) and non-hematological toxicity (50 patients, 34.2%). Hospitalization due to adverse events was required in 31 patients (21.2%). Patients with relative dose intensity (RDI) less than 80% showed similar survival to those with RDI 80% or higher. Conclusions: Irinotecan monotherapy was relatively safely performed as salvage-line treatment for AGC in Japanese clinical practice. Careful patient selection and intensive modification of the dose of irinotecan might possibly be associated with favorable survival.

UR - http://www.scopus.com/inward/record.url?scp=85027114002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027114002&partnerID=8YFLogxK

U2 - 10.1007/s10120-017-0759-9

DO - 10.1007/s10120-017-0759-9

M3 - Article

C2 - 28799048

AN - SCOPUS:85027114002

VL - 21

SP - 464

EP - 472

JO - Gastric Cancer

JF - Gastric Cancer

SN - 1436-3291

IS - 3

ER -